ANX Mast Therapeutics, Inc.

SAN DIEGO, Jan. 19 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that data from preclinical studies of ANX-530 (vinorelbine emulsion) will be presented at the 2006 American Association for Cancer Research (AACR) Annual Meeting, April 1-5 in Washington DC. An abstract entitled "A novel emulsion formulation of vinorelbine attenuates venous toxicity while maintaining antitumor efficacy" will also be published in the 2006 Proceedings of the American Association for Cancer Research. The preclinical studies were conducted by independent laboratories. "The presentation at AACR is a great opportunity to present independent preclinical results for ANX-530. We believe that the less vein-irritating IV formulation we are developing can eventually become an attractive alternative to currently available IV vinorelbine," said Evan M. Levine, ADVENTRX president and CEO. "We remain on track to file an investigational new drug (IND) application for ANX-530 in order to initiate a single, marketing- enabling bioequivalency trial in the first half of 2006." About ANX-530 ANX-530 is a novel emulsion formulation of vinorelbine tartrate. Vinorelbine is a chemotherapeutic agent indicated as a single agent or in combination with cisplatin for treatment of advanced non-small cell lung cancer (NSCLC). The Company plans to conduct a single bioequivalency study of ANX-530 as a marketing-enabling clinical trial, a plan that was recently affirmed by the US Food and Drug Administration (FDA). The Company currently plans to file an investigational new drug (IND) application in the first half of 2006. The proposed clinical trial will compare the bioequivalency of ANX-530 with that of vinorelbine in patients with advanced solid tumors. In addition, the Company plans to collect comparative data on vein irritation and other safety parameters as secondary endpoints. About ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. More information can be found on the Company's Web site at http://www.adventrx.com/. Forward Looking Statement This press release contains forward-looking statements, within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled "Risk Factors" in ADVENTRX's last quarterly report on Form 10-Q, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866 Web site: http://www.adventrx.com/ Company News On-Call: http://www.prnewswire.com/comp/920134.html

Copyright